Navigation Links
Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
Date:3/15/2010

LONDON and OXFORD, England, March 15, 2010 /PRNewswire/ -- Matrix Corporate Capital ("Matrix") and PharmaVentures Limited ("PharmaVentures") today announced the signing of a Memorandum of Understanding ("MOU") covering strategic transactions in the biotech, pharmaceutical and med tech sectors. The companies will work together to identify licensing, buyout, investment, IPO and consolidation opportunities which bring together both strategic expertise and capital from Europe's dedicated healthcare investors.

The MOU joins two firms with synergistic transactional capabilities in the healthcare life sciences space:

Matrix is a provider of a full range of corporate finance services to small and mid cap growth companies. They are able to service companies across the full corporate lifecycle, with access to financing from Series A venture finance through IPO, secondary placements and traded debt.

PharmaVentures is a leading specialist healthcare business advisory group assisting corporations in all aspects of strategic transactions, from strategy formulations to implementation. PharmaVentures has an extensive track record of successful strategic advisory mandates in the sector with over 17 years of experience and 450 assignments, for over 600 clients, in 38 countries.

Fintan Walton, Chief Executive of PharmaVentures said "For our clients our alliance with Matrix will create one of Europe's strongest teams in healthcare transactions and equity financing. Our clients have always demanded the best and a strong experienced healthcare team is essential to their own success. Matrix has excellent proven capabilities in corporate finance and we are delighted to have entered into this agreement."

Malcolm Le May, Chief Executive of Matrix Corporate Capital said "We are delighted to team our skills with those of PharmaVentures. It has an excellent track record with some of the largest names in the pharmaceutical sector. Many of these companies now face unprecedented change in their business models, with the pursuit of greater efficiency driving buyouts; assets sales and licensing. Matrix has access to both private and public sector-specific capital across Europe which, with PharmaVentures' help, will allow us to create innovative transactions around these assets."

About Matrix Group

Matrix Corporate Capital is part of Matrix Group which is a privately owned financial services business founded in 1987 other areas of expertise include Asset Management, Property, and Specialised Finance.To date Matrix has raised around GBP8 billion for its investment products and currently has circa GBP3 billion of funds under management. Matrix's staff of over 200 are based in the West End of London at One Vine Street. Matrix Group Limited is the holding company for the following business activities

About PharmaVentures

PharmaVentures Limited (http://www.pharmaventures.con) is based in Oxford, England and is a leading international corporate advisory firm supporting its clients' growth ambitions through licensing, joint ventures and M&A in the healthcare industry. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisors, investment companies and government bodies. It also produces the highly popular PharmaDeals(R) range of intelligence products including analysis tools and reports. In 2006 it launched the world's first dedicated online pharmaceutical television channel PharmaTelevision(R) ( http://www.pharmatelevision.com)

    Contact

    Matrix Corporate Capital LLP
    Steve Cox, Partner
    +44-203-206-7000

    PharmaVentures Limited
    Tibor Papp
    +44(0)1865-332700


SOURCE PharmaVentures Limited & Matrix Corporate Capital

Back to top
'/>"/>
SOURCE PharmaVentures Limited & Matrix Corporate Capital
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
2. BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis
3. BioNanomatrix Receives New NCI Grant to Support Development of Chip-Based Nanofluidics Systems for Cell Fractionation
4. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
5. TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction
6. Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications
7. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
8. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
9. Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc.
10. Engineers make first active matrix display using nanowires
11. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS ... the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US ... absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):